Presentation switch-injectable to inhalation

A biopharmaceutical company with an approved biological product in an intravenous injectable presentation wanted to switch to an inhaled presentation. Chimera assisted in establishing clinical protocols for Phase 3 clinical testing and technical specifications for pulmonary delivery preparation for an End of Phase 2 meeting with CBER.